Movalis

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

91 API Suppliers, 22 USDMF, 15 CEP/COS, 8 JDMF, 16 EU WC, 32 KDMF, 21 NDC API, 38 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

50 Drugs in Development

50 Drugs in Development

INTERMEDIATES

20 Intermediate Suppliers

20 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

339 FDF Dossiers, 64 FDA Orange Book, 69 Europe, 36 Canada, 34 Australia, 41 South Africa, 95 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, ORALLY DISINTEGRATING;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, ORALLY DISINTEGRATING;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SUSPENSION;ORAL - 7.5MG/5ML

RELATED EXCIPIENT COMPANIES

1 Minakem, 1 Evonik, 3 Rochem International Inc, 8 SPI Pharma, 11 DKSH, 8 Boai NKY Pharmaceuticals Ltd, 7 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 4 ACG Worldwide, 7 Actylis, 1 Alcedo Pharmachem, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 20 BASF, 1 CD Formulation, 7 DFE Pharma, 7 Gangwal Chemicals, 2 Ideal Cures, 4 Ingredion Pharma Solutions, 16 Kerry, 3 Keval Exports, 3 Lonza Capsugel, 12 Microlex e.U, 1 Nanjing Bold Chemical, 3 Nitika Pharmaceutical Specialities, 2 Novo Excipients, 5 Pharmatrans-Sanaq, 6 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 27 Roquette, 1 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 4 Silverline Chemicals, 2 Ulanqab Kema New Material, 4 Vasa Pharmachem, 2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

60 Fillers, Diluents & Binders, 40 Disintegrants & Superdisintegrants, 35 Direct Compression, 31 Granulation, 23 Thickeners and Stabilizers, 20 Lubricants & Glidants, 17 Taste Masking, 15 Chewable & Orodispersible Aids, 15 Coating Systems & Additives, 13 Co-Processed Excipients, 12 Film Formers & Plasticizers, 11 Controlled & Modified Release, 10 Solubilizers, 9 Parenteral, 8 Empty Capsules, 7 Topical, 5 Rheology Modifiers, 4 Emulsifying Agents, 3 API Stability Enhancers, 2 Coloring Agents, 1 Soft Gelatin, 1 Surfactant & Foaming Agents

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 1 Stock Recap #PipelineProspector, 53 News #PharmaBuzz

GLOBAL SALES INFORMATION

16 US Medicaid Prescriptions, 57 Regulatory FDF Prices, 1 Annual Reports

MARKET PLACE

35 APIs, 2 FDF Dossiers, 1 Intermediates

PATENTS & EXCLUSIVITIES

81 US Patents, 4 US Exclusivities, 2 Health Canada Patents

REF. STANDARDS & IMPURITIES

5 EDQM, 6 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 20938 / DOSAGE - TABLET;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
MELOXICAM(UNII: VG2QF83CGL) (MELOXICAM - UNII:VG2QF83CGL)	MELOXICAM	7.5mg

Drug Product Composition: Movalis

Movalis

Movalis

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

91 API Suppliers

22 USDMF

15 CEP/COS

8 JDMF

16 EU WC

32 KDMF

21 NDC API

38 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

50 Drugs in Development

INTERMEDIATES

20 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

339 FDF Dossiers

64 FDA Orange Book

69 Europe

36 Canada

34 Australia

41 South Africa

95 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, ORALLY DISINTEGRATING;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, ORALLY DISINTEGRATING;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SUSPENSION;ORAL - 7.5MG/5ML

RELATED EXCIPIENT COMPANIES

1 Minakem

1 Evonik

3 Rochem International Inc

8 SPI Pharma

11 DKSH

8 Boai NKY Pharmaceuticals Ltd

7 Gangwal Healthcare

3 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

4 ACG Worldwide

7 Actylis

1 Alcedo Pharmachem

8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

2 Ashland

20 BASF

1 CD Formulation

7 DFE Pharma

7 Gangwal Chemicals

2 Ideal Cures

4 Ingredion Pharma Solutions

16 Kerry

3 Keval Exports

3 Lonza Capsugel

12 Microlex e.U

1 Nanjing Bold Chemical

3 Nitika Pharmaceutical Specialities

2 Novo Excipients

5 Pharmatrans-Sanaq

6 Pluviaendo

4 Prachin Chemical

1 Qualicaps

27 Roquette

1 Seppic

5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

10 Sigachi Industries

4 Silverline Chemicals

2 Ulanqab Kema New Material

4 Vasa Pharmachem

2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

60 Fillers, Diluents & Binders

TABLET;ORAL - 15MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 7.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, ORALLY DISINTEGRATING;ORAL - 15MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, ORALLY DISINTEGRATING;ORAL - 7.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons